Mural Oncology PLC, based in Ireland, is a clinical-stage biotechnology firm utilizing its protein engineering platform to create cytokine-based immunotherapies for cancer, including programs like Nemvaleukin alfa. The company focuses on engineering interleukins such as IL-2, IL-12, and IL-18 to enhance immune responses against cancers with limited treatment options.
Susan Altschuller bought 10,000 shares of MURA on 14 August at $3.21 per share, worth a total of $32K. They now own 10,000 MURA shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
